BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, November 7, 2024
Breaking News: Best of BioWorld Science: Q3
See today's BioWorld Science
Home
» FFA1 and FFA4 receptor agonists disclosed in Dartmouth College patent
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Endocrine/metabolic
FFA1 and FFA4 receptor agonists disclosed in Dartmouth College patent
Oct. 29, 2024
No Comments
Dartmouth College has divulged fatty acid mimetics acting as free fatty acid FFA1 receptor (GPR40) and/or FFA4 receptor (GPR120) agonists reported to be useful for the treatment of obesity and type 2 diabetes.
BioWorld Science
Endocrine/metabolic
Patents